Upgrades Mkt Perform Outperform X

GMAB Genmab

William Blair

Upgrades Mkt Perform Outperform X

GMAB Genmab

Leerink Partners

$27

Initiated Buy X

GMAB Genmab

Redburn Atlantic

Resumed Equal-Weight X

GMAB Genmab

Morgan Stanley

$31

Downgrades Overweight Neutral X

GMAB Genmab

JP Morgan

Upgrades Sec Perform Outperform X

GMAB Genmab

RBC Capital Mkts

Upgrades Mkt Perform Outperform X

GMAB Genmab

BMO Capital Markets

$46 $48

Downgrades Neutral Sell X

GMAB Genmab

Citigroup

Upgrades Neutral Buy X

GMAB Genmab

UBS

Upgrades Hold Buy X

GMAB Genmab

Deutsche Bank

Initiated Underperform X

GMAB Genmab

Exane BNP Paribas

Downgrades Outperform Sec Perform X

GMAB Genmab

RBC Capital Mkts

Initiated Buy X

GMAB Genmab

BTIG Research

$44

Initiated Buy X

GMAB Genmab

HSBC Securities

Initiated Neutral X

GMAB Genmab

UBS

Initiated Underweight X

GMAB Genmab

Morgan Stanley

Downgrades Buy Neutral X

GMAB Genmab

Citigroup

Initiated Mkt Perform X

GMAB Genmab

William Blair

Downgrades Buy Hold X

GMAB Genmab

Deutsche Bank

Initiated Market Perform X

GMAB Genmab

BMO Capital Markets

$34.73

Initiated Market Perform X

GMAB Genmab

Cowen

$38

Upgrades Neutral Buy X

GMAB Genmab

UBS

Downgrades Buy Neutral X

GMAB Genmab

Guggenheim

Initiated Sell X

GMAB Genmab

Berenberg

Initiated Buy X

GMAB Genmab

Deutsche Bank

Downgrades Overweight Eq-Weight X

GMAB Genmab

Morgan Stanley

$41

Initiated Buy X

GMAB Genmab

Guggenheim

Initiated Overweight X

GMAB Genmab

Morgan Stanley

Initiated Outperform X

GMAB Genmab

RBC Capital Mkts

GMAB  Genmab A/S

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.